Therachon
Developing a novel biologic therapy for achondroplasia, the most common form of dwarfism
Developing a novel biologic therapy for achondroplasia, the most common form of dwarfism
Sectors
Healthcare
Life Sciences
First Invested
2015
Early
Company Status
Private
About
Team
Portfolio
Insights
About
Team
Portfolio
Insights
NEA Portfolio: Therachon